Positive Results from Phase III ECHELON-1 Trial Evaluating Brentuximab Vedotin in Frontline Advanced Hodgkin Lymphoma
Published on 28th June
ECHELON-1, a randomized, multicenter, phase III clinical trial evaluating brentiximab vedotin(Adcetris®) as part of a combination chemotherapy regimen in 1,334 patients with advanced Hodgkin Lymphoma, met primary endpoint, demonstrating a statistically significant improvement in modified progression-free survival (PFS) per Independent Review Facility assessment using the Revised Response Criteria for Malignant Lymphoma versus control.
This endpoint was chosen as it provides a clearer picture of the efficacy of frontline chemotherapy and eliminates the confounding impact of salvage and consolidation chemotherapies and radiotherapy. Secondary endpoints include overall survival, complete remission and safety.
The study, conducted in North America, Europe, South America, Australia, Asia and Africa, enrolled 1,334 patients who had a histologically-confirmed diagnosis of Stage III or IV classical Hodgkin lymphoma and had not been previously treated with systemic chemotherapy or radiotherapy.
Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Classical Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell expresses CD30.
Based on these results, Seattle Genetics and Takeda plan to submit an abstract for presentation during the 2017 annual meeting of the American Society of Hematology, to be held in Atlanta, GA, December 9-12, 2017. The companies are also planning to submit these results to regulatory authorities for approval in their respective territories.
Brentiximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma.
The drug is currently not approved as a frontline therapy for Hodgkin lymphoma.
Patients in ECHELON-1 were randomized to receive either a combination of brentiximab vedotin + AVD (Adriamycin, vinblastine, dacarbazine) or ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine), a recognized standard of care for frontline Hodgkin lymphoma.
The results of the ECHELON-1 trial demonstrated that combination treatment with brentiximab vedotin resulted in a statistically significant improvement in modified PFS versus the control arm as assessed by an Independent Review Facility (hazard ratio=0.770; p-value=0.035).
The two-year modified PFS rate for patients in the brentiximab vedotin arm was 82.1 percent compared to 77.2% in the control arm. Interim analysis of overall survival (OS), the key secondary endpoint, also trended in favor of the brentiximab vedotin + AVD arm.
The safety profile of brentiximab vedotin + AVD in the ECHELON-1 trial was consistent with that known for the single-agent components of the regimen.
The researchers observed an increased incidence of febrile neutropenia and peripheral neuropathy in the brentiximab vedotin + AVD arm. Febrile neutropenia was reduced through the use of prophylactic growth factors in a subset of patients, and peripheral neuropathy was managed through dose modifications. The control arm had an increased rate and severity of pulmonary toxicity.
“We are excited about the positive result which shows a statistically significant improvement in the primary endpoint of modified PFS,” said Dirk Huebner, MD., Executive Medical Director, Oncology Therapeutic Area Unit, Takeda Pharmaceutical Company. “The results of this trial signify an important step forward in the development of brentiximab vedotin and have the potential to change the treatment approach of frontline advanced Hodgkin lymphoma.”
“The outcome of the Phase III ECHELON-1 trial represents a significant milestone for the Hodgkin lymphoma community,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Seattle Genetics’ goal is to establish brentiximab vedotin as the foundation of care for CD30-expressing lymphomas, including Hodgkin lymphoma. Notably, this is the first clinical trial in frontline advanced Hodgkin lymphoma to show superior efficacy of a regimen that eliminates bleomycin.”
Last editorial review: June 28, 2017
Featured Image: Micrograph of Hodgkin lymphoma. Lymph node FNA specimen. Field stain. The micrograph shows a mixture of cells common in Hodgkin Lymphoma, including Eosinophils, Reed-Sternberg cells, Plasma cells and Histocytes. Courtesy: © 2017. Fotolia. Used with permission. Photo: Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Courtesy: © 2017. Seattle Genetics. Used with permission.
Copyright © 2017 InPress Media Group, LLC. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.